{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:05:24Z","timestamp":1761491124870},"reference-count":47,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>World Health Organization (WHO) declared coronavirus disease (COVID-19) a pandemic in March 2020. Currently almost every country in the world has reported cases with moderate to high mortality rates. The European Union (EU), the United States of America (USA) and the United Kingdom (UK) are the severely affected countries. Nevertheless, the WHO is very much concern about countries with weak health systems. The clinical characteristics of COVID-19 varies extensively, ranging from asymptomatic infections to severe as well as critical pneumonia with high mortality rates in the elderly and patients with co-morbid medical illness. Convalescent Plasma Therapy (CPT) has been successfully used in treating various viral disease outbreaks such as 1918 influenza pneumonia pandemic, poliomyelitis, measles, mumps, Machupo virus, Junin virus, Lassa virus, Ebola etc. High-titer specific antibodies maybe capable of binding to Coronavirus-19 (CoV-19) and neutralize the viral particles, inhibit entry to uninfected cells, and trigger potent effector mechanisms such as complement activation as well as phagocytosis. Therefore, in most countries with very weak health systems with no Intensive Care Units (ICUs) or trained ICU physicians, early initiation of CPT for severely COVID-19 patients may be rewarding. Therefore, solidarity control trials on CPT for COVID- 19 patients involving large number of patients are urgently needed.<\/jats:p>","DOI":"10.4081\/hr.2020.8630","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T09:10:52Z","timestamp":1606900252000},"page":"8630","source":"Crossref","is-referenced-by-count":4,"title":["Elucidating the Pivotal Role of Convalescent Plasma Therapy in Critically Ill COVID-19 Patients: A Review"],"prefix":"10.3390","volume":"12","author":[{"given":"Seidu","family":"Richard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvanus","family":"Kampo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maite","family":"Esquijarosa Hechavarria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/v12020135","article-title":"Return of the Coronavirus: 2019-nCoV","volume":"12","author":"Gralinski","year":"2020","journal-title":"Viruses"},{"key":"ref3","first-page":"368","article-title":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study","author":"Chen","year":"2020","journal-title":"BMJ"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"m1256","DOI":"10.1136\/bmj.m1256","article-title":"Covid-19: FDA approves use of convalescent plasma to treat critically ill patients","volume":"368","author":"Tanne","year":"2020","journal-title":"BMJ"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann Internal Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0002-9343(66)90103-3","article-title":"Bolivian hemorrhagic fever: a report of four cases","volume":"40","author":"Stinebaugh","year":"1966","journal-title":"Am J Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2007.10.010","article-title":"Treatment of Argentine hemorrhagic fever","volume":"78","author":"Enria","year":"2008","journal-title":"Antiviral Res"},{"key":"ref9","first-page":"2239","article-title":"Treatment of Argentine hemorrhagic fever with convalescent's plasma. 4433 cases","volume":"15","author":"Ruggiero","year":"1986","journal-title":"Presse Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0035-9203(84)90107-X","article-title":"The use of Lassa fever convalescent plasma in Nigeria","volume":"78","author":"Frame","year":"1984","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1469-0691.2004.00956.x","article-title":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients","volume":"10","author":"Soo","year":"2004","journal-title":"Clin Microbiol Infection"},{"key":"ref12","first-page":"309","article-title":"Treatment of severe acute respiratory syndrome with convalescent plasma","volume":"9","author":"Burnouf","year":"2003","journal-title":"Hong Kong Med J"},{"key":"ref13","first-page":"199","article-title":"Treatment of severe acute respiratory syndrome with convalescent plasma","volume":"9","author":"Wong","year":"2003","journal-title":"Hong Kong Med J"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","volume":"20","author":"Chen","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1378\/chest.12-2907","article-title":"Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection","volume":"144","author":"Hung","year":"2013","journal-title":"Chest"},{"key":"ref17","article-title":"Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion as an empirical treatment during outbreaks: interim guidance for national health authorities and blood transfusion services","year":"2014"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1186\/s40064-015-1490-9","article-title":"Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol","volume":"4","author":"Arabi","year":"2015","journal-title":"Springerplus"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13054-020-2818-6","article-title":"Treatment of COVID-19: old tricks for new challenges","volume":"24","author":"Cunningham","year":"2020","journal-title":"Crit Care"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"105924","DOI":"10.1016\/j.ijantimicag.2020.105924","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges","author":"Lai","year":"2020","journal-title":"Int J Antimicrobial Agents"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Bioscience Trends"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11655-020-3192-6","article-title":"Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs","volume":"26","author":"Luo","year":"2020","journal-title":"Chinese J Integrative Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/jama.2020.3633","article-title":"Care for critically ill patients with COVID-19","volume":"323","author":"Murthy","year":"2020","journal-title":"JAMA"},{"key":"ref26","first-page":"56","article-title":"Critical care response to a hospital outbreak of the 2019-nCoV infection in Shenzhen, China","volume":"24","author":"Liu","year":"2020","journal-title":"BioMed Central"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMc070359","article-title":"Treatment with convalescent plasma for influenza A (H5N1) infection","volume":"357","author":"Zhou","year":"2007","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","volume":"52","author":"Hung","year":"2011","journal-title":"Clin Infect Dis"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/dki346","article-title":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital","volume":"56","author":"Yeh","year":"2005","journal-title":"J Antimicrobial Chemother"},{"key":"ref30","article-title":"The selection and use of essential medicines. Report of the WHO Expert Committee, 2017 (including the 20th WHO model list of essential medicines and the 6th WHO model list of essential medicines for children)","year":"2017"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(16)31599-9","article-title":"Essential medicines for universal health coverage","volume":"389","author":"Wirtz","year":"2017","journal-title":"Lancet"},{"key":"ref32","article-title":"Selection of essential medicines at country level: using the WHO model list of essential medicines to update a national essential medicines list","year":"2020"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nature Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"138277","DOI":"10.1016\/j.scitotenv.2020.138277","article-title":"COVID-19: A promising cure for the global panic","author":"Vellingiri","year":"2020","journal-title":"Sci Total Environ"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12985-019-1182-0","article-title":"Coronavirus envelope protein: current knowledge","volume":"16","author":"Schoeman","year":"2019","journal-title":"Virol J"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"ref37","first-page":"26","article-title":"Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients","author":"Okba","year":"2020","journal-title":"Emerging Infect Dis"},{"key":"ref38","article-title":"Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications","author":"Wu","year":"2020","journal-title":"MedRxiv"},{"key":"ref39","first-page":"139479","article-title":"Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019","author":"Zhao","year":"2020","journal-title":"Clinical Infectious Diseases"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"e00461","DOI":"10.1128\/JCM.00461-20","article-title":"Evaluation of Nucleocapsid and Spike Proteinbased ELISAs for detecting antibodies against SARS-CoV-2","volume":"58","author":"Liu","year":"2020","journal-title":"J Clin Microbiol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1128\/JCM.42.6.2629-2635.2004","article-title":"Sensitive and specific monoclonal antibody- based capture enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute respiratory syndrome","volume":"42","author":"Che","year":"2004","journal-title":"J Clin Microbiol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10096-005-1378-7","article-title":"Doubleantigen sandwich ELISA for detection of antibodies to SARS-associated coronavirus in human serum","volume":"24","author":"Chen","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref43","first-page":"287","article-title":"Recombinant protein-based enzymelinked immunosorbent assay and immunochromatographic tests for detection of immunoglobulin G antibodies to severe acute respiratory syndrome (SARS) coronavirus in SARS patients","volume":"11","author":"Guan","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.chom.2020.03.002","article-title":"A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2","volume":"27","author":"Grifoni","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.2020.4940","article-title":"Convalescent Plasma to Treat COVID-19: Possibilities and Challenges","volume":"323","author":"Roback","year":"2020","journal-title":"JAMA"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/infdis\/jiaa228","article-title":"Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID- 19 Patients","volume":"222","author":"Zeng","year":"2020","journal-title":"J Infect Dis"},{"key":"ref47","article-title":"Potent neutralizing antibodies in the sera of convalescent COVID-19 patients are directed against conserved linear epitopes on the SARS-CoV-2 spike protein","author":"Poh","year":"2020","journal-title":"BioRxiv"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.pagepress.org\/journals\/index.php\/hr\/article\/download\/8630\/8460","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.pagepress.org\/journals\/index.php\/hr\/article\/download\/8630\/8476","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mdpi.com\/2038-8330\/12\/3\/8630\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T07:28:17Z","timestamp":1645601297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/12\/3\/8630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,2]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["hr.2020.8630"],"URL":"https:\/\/doi.org\/10.4081\/hr.2020.8630","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,2]]}}}